Page:Washington v. U.S. Food and Drug Administration (Order on Motion for Clarification, Apr. 13, 2023).pdf/6

 #:“altering the status quo and rights as it relates to the availability of Mifepristone under the current operative January 2023 Risk Evaluation and Mitigation Strategy under 21 U.S.C. § 355-1 in Plaintiff States and the District of Columbia.”

The District Court Executive is directed to enter this Order and furnish copies to counsel.

DATED April 13, 2023.